AR076164A1 - Inhibidores de anillos fusionados de hepatitis c - Google Patents
Inhibidores de anillos fusionados de hepatitis cInfo
- Publication number
- AR076164A1 AR076164A1 ARP100101000A ARP100101000A AR076164A1 AR 076164 A1 AR076164 A1 AR 076164A1 AR P100101000 A ARP100101000 A AR P100101000A AR P100101000 A ARP100101000 A AR P100101000A AR 076164 A1 AR076164 A1 AR 076164A1
- Authority
- AR
- Argentina
- Prior art keywords
- heterocycle
- heteroaryl
- group
- cycloalkyl
- aryl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Gastroenterology & Hepatology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Peptides Or Proteins (AREA)
Abstract
Composiciones farmacéuticas y terapias de combinacion para el tratamiento de la hepatitis C. Reivindicacion 1: Un compuesto que tiene la formula (1) donde D o bien está presente o ausente, y si está presente, se selecciona del grupo que consiste en -CR2CR2-, -CR2-, -NRN-, -O- y -S-, donde RN es H, -OH, alquilo C1-12, heteroalquilo C1-12, cicloalquilo, heterociclo, arilo, heteroarilo, aralquilo, alcoxi, alcoxicarbonilo, alcanoílo, carbamoilo, sulfonilo sustituido, sulfonato y sulfonamida, y cada R se selecciona de manera independiente del grupo que consiste en hidrogeno, -OH, -CN, -NO2, halogeno, alquilo C1-12, heteroalquilo C1-12, cicloalquilo, heterociclo, arilo, heteroarilo, aralquilo, alcoxi, alcoxicarbonilo, alcanoilo, carbamoilo, sulfonilo sustituido, sulfonato, sulfonamida y amino; A y E son, de manera independiente, -CR2-, -CR=, -CR2-CR2, -CR=CR-, -N=CR-, -(CR2)a-N(RN)-(CR2)a, -(CR2)a-C(O)-N(RN)-(CR2)a-, -CR2)a-N(RN)-C(O)-(CR2)a- o -(CR2)b-O-(CR2)b-, donde RN se selecciona del grupo que consiste en H, -OH, alquilo C1-12, heteroalquilo C1-12, cicloalquilo, heterociclo, arilo, heteroarilo, aralquilo, alcoxi, alcoxicarbonilo, alcanoilo, carbamoilo, sulfonilo sustituido, sulfonato y sulfonamida; cada R se selecciona de modo independiente del grupo que consiste en hidrogeno, -OH, -CN, -NO2, halogeno, alquilo C1-12, heteroalquilo C1-12, cicloalquilo, heterociclo, arilo, heteroarilo, aralquilo, alcoxi, alcoxicarbonilo, alcanoilo, carbamoílo, sulfonilo sustituido, sulfonato, sulfonamida y amino, donde dos R' , ya sea ambos en un solo C, ya sea en C adjuntos, junto con el C o los C a los cuales están unidos, forman, opcionalmente, un ciclo; y donde son posibles dos R en un C, el C puede estar opcionalmente ligado a un solo R con un doble enlace; cada a y b son, de manera independiente, 0; 1; 2; o 3, con la condicion de que si D está presente, ambos b no son 0; y RN y R pueden estar reemplazados por un enlace a D si D está presente; si D está ausente, A y E, además pueden ser, independientemente, un enlace, -O-, -S-, -S(O2)-, -S(O)-, -C(O)- o -N=; y con la condicion de que si W y W' son ambos anillos de 5 miembros, A y E o bien son ambos un enlace, o ambos son diferentes de un enlace; cada Ra se selecciona de manera independiente del grupo que consiste en -OH, -CN, -NO2, halogeno, alquilo C1-12, heteroalquilo C1-12, cicloalquilo, heterociclo, arilo, heteroarilo, aralquilo, alcoxi, alcoxicarbonilo, alcanoilo, carbamoílo, sulfonilo sustituido, sulfonato, sulfonamida y amino; cada r es, independientemente, 0; 1; 2 o 3; W y W' se seleccionan de manera independiente del grupo que consiste en formulas (2) donde X1 es CH2, NR, O o S; Y1, Y2 y Z1 son, de modo independiente, CH o N; X2 es NH, O o S; W y W', de manera independiente, están opcionalmente sustituidos con uno o más sustituyentes seleccionados del grupo que consiste en -OH, -CN, -NO2, halogeno, alquilo C1-12, heteroalquilo C1-12, cicloalquilo, heterociclo, arilo, heteroarilo, aralquilo, alcoxi, alcoxicarbonilo, alcanoilo, carbamoílo, sulfonilo sustituido, sulfonato, sulfonamida y amino; y Cy es un grupo monocíclico, bicíclico o tricíclico de 5 a 12 miembros cicloalquilo, heterociclo, arilo, o heteroarilo donde hasta tres heteroátomos son, independientemente, N, S u O, y está opcionalmente sustituido con uno o más sustituyentes seleccionados del grupo que consiste en -OH, -CN, -NO2, halogeno, alquilo C1-12, heteroalquilo C1-12, cicloalquilo, heterociclo, arilo, heteroarilo, aralquilo, alcoxi, alcoxicarbonilo, alcanoilo, carbamoílo, sulfonilo sustituido, sulfonato, sulfonamida y amino; cada Rc, Rd, Re y Rf se seleccionan de manera independiente del grupo que consiste en: hidrogeno, alquilo C1-8, heteroalquilo C1-8, aralquilo y un anillo de 4 a 8 miembros que puede ser cicloalquilo, heterociclo, heteroarilo o arilo, donde: cada heteroátomo, si se presenta, es de manera independiente N, O o S; cada Rc, Rd, Re y Rf pueden estar opcionalmente sustituidos con alquilo C1-8, heteroalquilo C1-8, aralquilo, o un anillo de 4 a 8 miembros que puede ser cicloalquilo, heterociclo, heteroarilo o arilo, y donde cada heteroátomo, si se presenta, es, de modo independiente, N, O o S; Rc y Rd están opcionalmente unidos para formar un heterociclo de 4 a 8 miembros, que, en forma opcional, está fusionado a otro anillo heteroarilo o heterociclo de 3 a 5 miembros; y Re y Rf están opcionalmente unidos para formar un heterociclo de 4 a 8 miembros, que, en forma opcional, está fusionado a otro anillo heteroarilo o heterociclo de 3 a 5 miembros; Y e Y' son, de manera independiente, carbono o nitrogeno; y Z y Z1 se seleccionan de manera independiente del grupo que consiste en hidrogeno, alquilo C1-8, heteroalquilo C1-8, cicloalquilo, heterociclo, arilo, heteroarilo, aralquilo, 1-3 aminoácidos, -[U-(CR42)t-NR5-C(R42)t]u-U- (CR42)t-NR7-(CR42)t-R8, -U-(CR42) t-R8, y -[U-(CR42)t-NR5-(CR42)t]u-U-(CR42)t-O-(CR42)t-R8, donde U se selecciona del grupo que consiste en -C(O)-, -C(S)- y -S(O)2-, cada R4, R5 y R7 se seleccionan de manera independiente del grupo que consiste en hidrogeno, alquilo C1-8, heteroalquilo C1-8, cicloalquilo, heterociclo, arilo, heteroarilo y aralquilo; R8 se selecciona del grupo que consiste en hidrogeno, alquilo C1-8, heteroalquilo C1-8, cicloalquilo, heterociclo, arilo, heteroarilo, aralquilo, -C(O)-R81, -C(S)-R81, -C(O)-O-R81, -C(O)-N-R812, -S(O)2-R81 y -S(O)2-N-R812, donde cada R81 se selecciona de modo independiente del grupo que consiste en hidrogeno, alquilo C1-8, heteroalquilo C1-8, cicloalquilo, heterociclo, arilo, heteroarilo y aralquilo; opcionalmente, R7 y R8 juntos forman un anillo de 4-7 miembros; cada t es, independientemente, 0; 1; 2; 3; o 4; y u es 0; 1; o 2.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US16434209P | 2009-03-27 | 2009-03-27 | |
| US21488309P | 2009-04-28 | 2009-04-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR076164A1 true AR076164A1 (es) | 2011-05-26 |
Family
ID=42781523
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP100101000A AR076164A1 (es) | 2009-03-27 | 2010-03-29 | Inhibidores de anillos fusionados de hepatitis c |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US9150554B2 (es) |
| EP (1) | EP2410843A4 (es) |
| JP (1) | JP5735482B2 (es) |
| KR (1) | KR20110131312A (es) |
| CN (1) | CN102427726B (es) |
| AR (1) | AR076164A1 (es) |
| AU (1) | AU2010229795A1 (es) |
| BR (1) | BRPI1012282A2 (es) |
| CA (1) | CA2755658A1 (es) |
| CL (1) | CL2011002377A1 (es) |
| CO (1) | CO6450600A2 (es) |
| EA (1) | EA201190224A1 (es) |
| HK (1) | HK1166446A1 (es) |
| IL (1) | IL215202A0 (es) |
| MX (1) | MX2011010132A (es) |
| PE (1) | PE20120773A1 (es) |
| SG (1) | SG174883A1 (es) |
| TW (1) | TW201038560A (es) |
| WO (1) | WO2010111534A1 (es) |
| ZA (1) | ZA201107753B (es) |
Families Citing this family (101)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102245604A (zh) | 2008-12-23 | 2011-11-16 | 雅培制药有限公司 | 抗病毒化合物 |
| JP2012513409A (ja) | 2008-12-23 | 2012-06-14 | アボット・ラボラトリーズ | 抗ウイルス化合物 |
| US8314135B2 (en) | 2009-02-09 | 2012-11-20 | Enanta Pharmaceuticals, Inc. | Linked dibenzimidazole antivirals |
| US8394968B2 (en) | 2009-02-17 | 2013-03-12 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US8188132B2 (en) | 2009-02-17 | 2012-05-29 | Enanta Pharmaceuticals, Inc. | Linked dibenzimidazole derivatives |
| US8242156B2 (en) | 2009-02-17 | 2012-08-14 | Enanta Pharmaceuticals, Inc. | Linked dibenzimidazole derivatives |
| US8673954B2 (en) | 2009-02-27 | 2014-03-18 | Enanta Pharmaceuticals, Inc. | Benzimidazole derivatives |
| US9765087B2 (en) | 2009-02-27 | 2017-09-19 | Enanta Pharmaceuticals, Inc. | Benzimidazole derivatives |
| US8101643B2 (en) | 2009-02-27 | 2012-01-24 | Enanta Pharmaceuticals, Inc. | Benzimidazole derivatives |
| US8507522B2 (en) | 2009-03-06 | 2013-08-13 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
| KR20110131312A (ko) | 2009-03-27 | 2011-12-06 | 프레시디오 파마슈티칼스, 인코포레이티드 | 융합된 고리 ｃ형 간염 억제제 |
| ME02418B (me) | 2009-03-27 | 2016-09-20 | Merck Sharp & Dohme | Inhibitori replikacije virusa hepatitisa c |
| US20190127365A1 (en) | 2017-11-01 | 2019-05-02 | Merck Sharp & Dohme Corp. | Inhibitors of hepatitis c virus replication |
| US8796466B2 (en) | 2009-03-30 | 2014-08-05 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| TW201038559A (en) | 2009-04-09 | 2010-11-01 | Bristol Myers Squibb Co | Hepatitis C virus inhibitors |
| US8143414B2 (en) | 2009-04-13 | 2012-03-27 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| RU2541571C2 (ru) | 2009-04-15 | 2015-02-20 | Эббви Инк. | Противовирусные соединения |
| JP2012526834A (ja) * | 2009-05-12 | 2012-11-01 | シェーリング コーポレイション | ウイルス疾患治療に有用な縮合型三環式アリール化合物 |
| CN109020961A (zh) | 2009-05-13 | 2018-12-18 | 吉利德制药有限责任公司 | 抗病毒化合物 |
| US8211928B2 (en) | 2009-05-29 | 2012-07-03 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US8138215B2 (en) | 2009-05-29 | 2012-03-20 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US8716454B2 (en) | 2009-06-11 | 2014-05-06 | Abbvie Inc. | Solid compositions |
| US8937150B2 (en) | 2009-06-11 | 2015-01-20 | Abbvie Inc. | Anti-viral compounds |
| US9394279B2 (en) | 2009-06-11 | 2016-07-19 | Abbvie Inc. | Anti-viral compounds |
| TWI469780B (zh) | 2009-06-11 | 2015-01-21 | Abbvie Bahamas Ltd | 抗病毒化合物 |
| US8221737B2 (en) | 2009-06-16 | 2012-07-17 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
| US8609648B2 (en) | 2009-07-02 | 2013-12-17 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
| CN102656160A (zh) | 2009-07-16 | 2012-09-05 | 顶点制药公司 | 用于治疗或预防黄病毒感染的苯并咪唑类似物 |
| AU2010276537B2 (en) | 2009-07-27 | 2015-04-16 | Gilead Sciences, Inc. | Fused heterocyclic compounds as ion channel modulators |
| PE20120993A1 (es) | 2009-09-04 | 2012-08-22 | Janssen Pharmaceuticals Inc | Derivados bifenilicos como antivirales |
| US8822700B2 (en) | 2009-09-11 | 2014-09-02 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
| US8703938B2 (en) | 2009-09-11 | 2014-04-22 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
| WO2011031904A1 (en) | 2009-09-11 | 2011-03-17 | Enanta Pharmaceuticals, Inc | Hepatitis c virus inhibitors |
| US8759332B2 (en) | 2009-09-11 | 2014-06-24 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
| US8927709B2 (en) | 2009-09-11 | 2015-01-06 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
| US8815928B2 (en) | 2009-09-11 | 2014-08-26 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
| US20110274648A1 (en) | 2009-11-11 | 2011-11-10 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
| US20110269956A1 (en) | 2009-11-11 | 2011-11-03 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
| US20110281910A1 (en) | 2009-11-12 | 2011-11-17 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
| US8653070B2 (en) | 2009-12-14 | 2014-02-18 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
| US8377980B2 (en) | 2009-12-16 | 2013-02-19 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| CN104530079B (zh) * | 2009-12-18 | 2017-10-20 | 北京凯因科技股份有限公司 | C型肝炎病毒复制的新型抑制剂 |
| US8362020B2 (en) | 2009-12-30 | 2013-01-29 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| KR20120107529A (ko) | 2010-01-25 | 2012-10-02 | 이난타 파마슈티칼스, 인코포레이티드 | Ｃ형 간염 바이러스 억제제 |
| US8933110B2 (en) | 2010-01-25 | 2015-01-13 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
| US8623814B2 (en) | 2010-02-23 | 2014-01-07 | Enanta Pharmaceuticals, Inc. | Antiviral agents |
| US8178531B2 (en) | 2010-02-23 | 2012-05-15 | Enanta Pharmaceuticals, Inc. | Antiviral agents |
| AU2010347272A1 (en) | 2010-03-04 | 2012-09-20 | Enanta Pharmaceuticals, Inc. | Combination pharmaceutical agents as inhibitors of HCV replication |
| WO2011119853A1 (en) | 2010-03-24 | 2011-09-29 | Vertex Pharmaceuticals Incorporated | Analogues for the treatment or prevention of flavivirus infections |
| US9127021B2 (en) | 2010-04-09 | 2015-09-08 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
| WO2011153396A1 (en) | 2010-06-04 | 2011-12-08 | Enanta Pharmaceuticals, Inc | Hepatitis c virus inhibitors |
| NZ605440A (en) | 2010-06-10 | 2014-05-30 | Abbvie Bahamas Ltd | Solid compositions comprising an hcv inhibitor |
| MX2012015096A (es) | 2010-07-02 | 2013-05-28 | Gilead Sciences Inc | Compuestos heterociclicos fusionados como moduladores del canal ion. |
| WO2012003642A1 (en) * | 2010-07-09 | 2012-01-12 | Merck Sharp & Dohme Corp. | Fused tricyclic compounds and use thereof for treating viral diseases |
| WO2012018534A2 (en) * | 2010-07-26 | 2012-02-09 | Schering Corporation | Substituted biphenylene compounds and methods of use thereof for the treatment of viral diseases |
| EP2603080A4 (en) | 2010-08-12 | 2014-01-22 | Enanta Pharm Inc | HEPATITIS C-VIRUS HEMMER |
| JP2013540122A (ja) | 2010-09-29 | 2013-10-31 | メルク・シャープ・エンド・ドーム・コーポレイション | 縮合四環式化合物誘導体およびウィルス疾患治療のためのそれの使用方法 |
| US8999967B2 (en) | 2010-09-29 | 2015-04-07 | Presidio Pharmaceuticals, Inc. | Tricyclic fused ring inhibitors of hepatitis C |
| NZ726475A (en) | 2010-11-17 | 2018-07-27 | Gilead Pharmasset Llc | Antiviral compounds |
| RU2452735C1 (ru) | 2010-11-30 | 2012-06-10 | Александр Васильевич Иващенко | Замещенные азолы, противовирусный активный компонент, фармацевтическая композиция, способ получения и применения |
| US8552047B2 (en) | 2011-02-07 | 2013-10-08 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| WO2012122716A1 (en) * | 2011-03-17 | 2012-09-20 | Merck Sharp & Dohme Corp. | Tetracyclic xanthene derivatives and methods of use thereof for treatment of viral diseases |
| EP2707361B1 (en) | 2011-05-10 | 2017-08-23 | Gilead Sciences, Inc. | Fused heterocyclic compounds as sodium channel modulators |
| US9546160B2 (en) | 2011-05-12 | 2017-01-17 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US10201584B1 (en) | 2011-05-17 | 2019-02-12 | Abbvie Inc. | Compositions and methods for treating HCV |
| WO2012158861A2 (en) | 2011-05-18 | 2012-11-22 | Enanta Pharmaceuticals, Inc. | Processes for the preparation of 5-azaspiro[2.4]heptane-6-carboxylic acid and its derivatives |
| NO3175985T3 (es) | 2011-07-01 | 2018-04-28 | ||
| TWI622583B (zh) | 2011-07-01 | 2018-05-01 | 基利科學股份有限公司 | 作為離子通道調節劑之稠合雜環化合物 |
| US9303061B2 (en) | 2011-07-09 | 2016-04-05 | Sunshine Luke Pharma Co., Ltd. | Spiro compounds as Hepatitis C virus inhibitors |
| EP2741746A4 (en) * | 2011-08-08 | 2014-12-31 | Glaxosmithkline Llc | CHEMICAL COMPOUNDS |
| WO2013030750A1 (en) | 2011-09-01 | 2013-03-07 | Lupin Limited | Antiviral compounds |
| DE202012013074U1 (de) | 2011-09-16 | 2014-10-29 | Gilead Pharmasset Lcc | Zusammensetzungen zur Behandlung von HCV |
| EP2635588B1 (en) | 2011-11-16 | 2015-06-10 | Gilead Pharmasset LLC | Condensed imidazolylimidazoles as antiviral compounds |
| US9034832B2 (en) | 2011-12-29 | 2015-05-19 | Abbvie Inc. | Solid compositions |
| US9326973B2 (en) | 2012-01-13 | 2016-05-03 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| AU2013217224B2 (en) | 2012-02-10 | 2017-04-06 | Lupin Limited | Antiviral compounds with a dibenzooxaheterocycle moiety |
| US20130309196A1 (en) | 2012-05-16 | 2013-11-21 | Gilead Sciences, Inc. | Antiviral compounds |
| CN103420991B (zh) * | 2012-05-17 | 2017-07-07 | 乳源东阳光药业有限公司 | 作为丙型肝炎抑制剂的吡咯烷衍生物及其在药物中的应用 |
| TWI610916B (zh) | 2012-08-03 | 2018-01-11 | 廣東東陽光藥業有限公司 | 作爲丙型肝炎抑制劑的橋環化合物及其在藥物中的應用 |
| US9802949B2 (en) * | 2012-11-29 | 2017-10-31 | Sunshine Lake Pharma Co., Ltd. | Fused ring compounds as hepatitis C virus inhibitors, pharmaceutical compositions and uses thereof |
| US9416139B2 (en) | 2012-11-29 | 2016-08-16 | Sunshine Lake Pharma Co., Ltd. | Spiro ring compound as hepatitis C virus (HCV) inhibitor and uses thereof |
| WO2014110687A1 (en) | 2013-01-16 | 2014-07-24 | Merck Sharp & Dohme Corp. | Thiazolyl-substitued tetracyclic compounds and methods of use thereof for treatment of viral diseases |
| SI2950786T1 (sl) | 2013-01-31 | 2020-03-31 | Gilead Pharmasset Llc | Formulacija kombinacije dveh protivirusnih spojin |
| RU2507201C1 (ru) | 2013-02-07 | 2014-02-20 | Александр Васильевич Иващенко | Алкил [(s)-1-((s)-2-{5-[4-(4-{2-[(s)-1-((s)-2-метоксикарбониламино-3-метил-бутирил)-пирролидин-2-ил]-3н-имидазол-4-ил}-бута-1,3-диинил)-фенил]-1н-имидазол-2-ил}-пирролидин-1-карбонил)-2-метил-пропил]-карбамат нафталин-1,5-дисульфонат, фармацевтическая композиция, лекарственное средство, способ лечения вирусных заболеваний |
| US11484534B2 (en) | 2013-03-14 | 2022-11-01 | Abbvie Inc. | Methods for treating HCV |
| US9717712B2 (en) | 2013-07-02 | 2017-08-01 | Bristol-Myers Squibb Company | Combinations comprising tricyclohexadecahexaene derivatives for use in the treatment of hepatitis C virus |
| US20150023913A1 (en) | 2013-07-02 | 2015-01-22 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
| US9775831B2 (en) | 2013-07-17 | 2017-10-03 | Bristol-Myers Squibb Company | Combinations comprising biphenyl derivatives for use in the treatment of HCV |
| ES2900570T3 (es) | 2013-08-27 | 2022-03-17 | Gilead Pharmasset Llc | Formulación de combinación de dos compuestos antivirales |
| WO2015103490A1 (en) | 2014-01-03 | 2015-07-09 | Abbvie, Inc. | Solid antiviral dosage forms |
| US9738629B2 (en) | 2014-01-23 | 2017-08-22 | Sunshine Lake Pharma Co., Ltd. | Bridged ring compounds as Hepatitis C virus inhibitors, pharmaceutical compositions and uses thereof |
| TWI721947B (zh) | 2014-06-11 | 2021-03-21 | 美商基利法瑪席特有限責任公司 | 抗病毒化合物的固態形式 |
| US10617675B2 (en) | 2015-08-06 | 2020-04-14 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| NZ745957A (en) | 2016-04-07 | 2020-07-31 | Glaxosmithkline Ip Dev Ltd | Heterocyclic amides useful as protein modulators |
| WO2017181383A1 (en) * | 2016-04-21 | 2017-10-26 | Merck Sharp & Dohme Corp. | Hepatitis c virus inhibitors |
| PE20210640A1 (es) | 2018-02-13 | 2021-03-23 | Gilead Sciences Inc | Inhibidores pd-1/pd-l1 |
| TWI712412B (zh) | 2018-04-19 | 2020-12-11 | 美商基利科學股份有限公司 | Pd‐1/pd‐l1抑制劑 |
| ES2962674T3 (es) | 2018-07-13 | 2024-03-20 | Gilead Sciences Inc | Inhibidores PD-1/PD-L1 |
| CN112955435B (zh) | 2018-10-24 | 2024-09-06 | 吉利德科学公司 | Pd-1/pd-l1抑制剂 |
| CN117460734A (zh) | 2021-05-21 | 2024-01-26 | 吉利德科学公司 | 作为寨卡病毒抑制剂的五环衍生物 |
| IL309232A (en) | 2021-06-14 | 2024-02-01 | Scorpion Therapeutics Inc | History of urea which can be used to treat cancer |
Family Cites Families (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL127610C (es) | 1965-06-23 | |||
| CH532608A (de) * | 1969-12-17 | 1973-01-15 | Ciba Geigy Ag | Verfahren zur Herstellung von Bis-aroxazolyl-Verbindungen |
| CH553807A (de) * | 1970-12-23 | 1974-09-13 | Sandoz Ag | Verfahren zur herstellung von dibenzthiophendioxidderivaten. |
| US3808206A (en) | 1971-06-29 | 1974-04-30 | Richardson Merrell Inc | Bis-basic ketones of phenoxathiins and antiviral compositions thereof |
| US4371690A (en) | 1979-07-12 | 1983-02-01 | E. I. Du Pont De Nemours And Company | Heat-resistant rigid polymers from difunctional 9,10-dihydro-9,10-ethanoanthracenes |
| US5288914A (en) | 1984-08-27 | 1994-02-22 | The Dow Chemical Company | Poly(arylcyclobutenes) |
| US5288924A (en) * | 1992-09-18 | 1994-02-22 | Mobil Oil Corporation | Process for starting up an olefin hydration reactor |
| US5807876A (en) | 1996-04-23 | 1998-09-15 | Vertex Pharmaceuticals Incorporated | Inhibitors of IMPDH enzyme |
| US6054472A (en) | 1996-04-23 | 2000-04-25 | Vertex Pharmaceuticals, Incorporated | Inhibitors of IMPDH enzyme |
| CN1515248A (zh) | 1996-04-23 | 2004-07-28 | ��̩��˹ҩ��ɷ�����˾ | 用作肌苷-5'-一磷酸脱氢酶抑制剂的脲衍生物 |
| EP2314598A1 (en) | 1996-10-18 | 2011-04-27 | Vertex Pharmaceuticals Incorporated | Inhibitors of Hepatitis C virus NS3 serine protease |
| GB9623908D0 (en) | 1996-11-18 | 1997-01-08 | Hoffmann La Roche | Amino acid derivatives |
| DK0966465T3 (da) | 1997-03-14 | 2003-10-20 | Vertex Pharma | Inhibitorer af IMPDH-enzymer |
| US6010848A (en) | 1997-07-02 | 2000-01-04 | Smithkline Beecham Corporation | Screening methods using an atpase protein from hepatitis C virus |
| HUP0100100A3 (en) | 1997-08-11 | 2001-12-28 | Boehringer Ingelheim Ca Ltd | Hepatitis c inhibitor peptide analogues, pharmaceutical compositions comprising thereof and their use |
| DE69925918T2 (de) | 1998-07-27 | 2006-05-11 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | Diketosäure-derivate als hemmstoffe von polymerasen |
| US6323180B1 (en) | 1998-08-10 | 2001-11-27 | Boehringer Ingelheim (Canada) Ltd | Hepatitis C inhibitor tri-peptides |
| CN1325309A (zh) | 1998-08-21 | 2001-12-05 | 维洛药品公司 | 用于治疗或预防病毒感染和相关疾病的化合物、组合物和方法 |
| WO2000013708A1 (en) | 1998-09-04 | 2000-03-16 | Viropharma Incorporated | Methods for treating or preventing viral infections and associated diseases |
| EP1115286A4 (en) | 1998-09-25 | 2003-07-23 | Viropharma Inc | METHOD FOR TREATING AND PREVENTING VIRAL INFECTIONS AND DISEASES RELATED TO THEM |
| CZ301802B6 (cs) | 1999-03-19 | 2010-06-30 | Vertex Pharmaceuticals Incorporated | Deriváty mocoviny jako inhibitory IMPDH a farmaceutické prostredky s jejich obsahem |
| US6242602B1 (en) * | 1999-03-29 | 2001-06-05 | Gentex Corporation | One pot synthesis of 5,10-dihydrophenazine compounds and 5,10-substituted dihydrophenazines |
| AU1262001A (en) | 1999-11-04 | 2001-05-14 | Biochem Pharma Inc. | Method for the treatment or prevention of flaviviridae viral infection using nucleoside analogues |
| EP1292310A1 (en) | 2000-05-10 | 2003-03-19 | SmithKline Beecham Corporation | Novel anti-infectives |
| US6448281B1 (en) | 2000-07-06 | 2002-09-10 | Boehringer Ingelheim (Canada) Ltd. | Viral polymerase inhibitors |
| SV2003000617A (es) | 2000-08-31 | 2003-01-13 | Lilly Co Eli | Inhibidores de la proteasa peptidomimetica ref. x-14912m |
| EP1256628A3 (en) | 2001-05-10 | 2003-03-19 | Agouron Pharmaceuticals, Inc. | Hepatitis c virus (hcv) ns5b rna polymerase and mutants thereof |
| EP1395571A1 (en) | 2001-06-11 | 2004-03-10 | Shire Biochem Inc. | Compounds and methods for the treatment or prevention of flavivirus infections |
| BR0210357A (pt) | 2001-06-11 | 2004-06-29 | Shire Biochem Inc | Composto e métodos para o tratamento ou a prevenção de infecções pelo flavivìrus |
| AR035543A1 (es) | 2001-06-26 | 2004-06-16 | Japan Tobacco Inc | Agente terapeutico para la hepatitis c que comprende un compuesto de anillo condensado, compuesto de anillo condensado, composicion farmaceutica que lo comprende, compuestos de benzimidazol, tiazol y bifenilo utiles como intermediarios para producir dichos compuestos, uso del compuesto de anillo con |
| JP2003212846A (ja) * | 2001-06-26 | 2003-07-30 | Japan Tobacco Inc | 縮合環化合物及びｃ型肝炎治療剤 |
| US6841566B2 (en) | 2001-07-20 | 2005-01-11 | Boehringer Ingelheim, Ltd. | Viral polymerase inhibitors |
| EP2335700A1 (en) | 2001-07-25 | 2011-06-22 | Boehringer Ingelheim (Canada) Ltd. | Hepatitis C virus polymerase inhibitors with a heterobicylic structure |
| UA85366C2 (en) * | 2001-07-25 | 2009-01-26 | Бёрингер Ингельхайм (Канада) Лтд. | Viral polymerase inhibitors |
| EP1440070A1 (en) | 2001-11-02 | 2004-07-28 | Glaxo Group Limited | 4-(5-membered)-heteroaryl acyl pyrrolidine derivatives as hcv inhibitors |
| US20050009873A1 (en) | 2001-11-02 | 2005-01-13 | Gianpaolo Bravi | Acyl dihydro pyrrole derivatives as hcv inhibitors |
| ES2289161T3 (es) | 2001-11-02 | 2008-02-01 | Glaxo Group Limited | Derivados de 4-(heteroaril de 6 miembros)-acil pirrolidina como inhibidores de hcv. |
| AR047793A1 (es) | 2004-01-30 | 2006-02-22 | Medivir Ab | Inhibidores de la serina proteasa ns-3 del vhc |
| US20080096848A1 (en) | 2004-09-29 | 2008-04-24 | Cytovia Inc. | Substituted N-Aryl-9-Oxo-9H-Fluorene-1-Carboxamides and Analogs as Activators of Caspases and Inducers of Apoptosis |
| US7355199B2 (en) * | 2004-11-02 | 2008-04-08 | E.I. Du Pont De Nemours And Company | Substituted anthracenes and electronic devices containing the substituted anthracenes |
| DE102005022020A1 (de) * | 2005-05-12 | 2006-11-23 | Merckle Gmbh | Dibenzocycloheptanverbindungen und pharmazeutische Mittel, welche diese Verbindungen enthalten |
| US8143288B2 (en) | 2005-06-06 | 2012-03-27 | Bristol-Myers Squibb Company | Inhibitors of HCV replication |
| US8329159B2 (en) * | 2006-08-11 | 2012-12-11 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US7759495B2 (en) * | 2006-08-11 | 2010-07-20 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US7745636B2 (en) | 2006-08-11 | 2010-06-29 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US7659270B2 (en) * | 2006-08-11 | 2010-02-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US7741347B2 (en) * | 2007-05-17 | 2010-06-22 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US7728027B2 (en) * | 2007-08-08 | 2010-06-01 | Bristol-Myers Squibb Company | Process for synthesizing compounds useful for treating hepatitis C |
| US8629171B2 (en) * | 2007-08-08 | 2014-01-14 | Bristol-Myers Squibb Company | Crystalline form of methyl ((1S)-1-((25)-2-(5-(4'-(2-((25)-1((2S)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)-2-pyrrolidinyl)-1H-imidazol-2-yl)-1-pyrrolidinyl)carbonyl)-2-methylpropyl)carbamate dihydrochloride salt |
| US7704992B2 (en) * | 2008-02-13 | 2010-04-27 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| JP5266786B2 (ja) * | 2008-02-20 | 2013-08-21 | 富士ゼロックス株式会社 | 新規なフェノチアジン化合物 |
| WO2010096462A1 (en) * | 2009-02-17 | 2010-08-26 | Enanta Pharmaceuticals, Inc | Linked diimidazole derivatives |
| KR20110131312A (ko) | 2009-03-27 | 2011-12-06 | 프레시디오 파마슈티칼스, 인코포레이티드 | 융합된 고리 ｃ형 간염 억제제 |
-
2010
- 2010-03-25 KR KR1020117025221A patent/KR20110131312A/ko not_active Application Discontinuation
- 2010-03-25 SG SG2011067683A patent/SG174883A1/en unknown
- 2010-03-25 WO PCT/US2010/028730 patent/WO2010111534A1/en active Application Filing
- 2010-03-25 CN CN201080021446.2A patent/CN102427726B/zh not_active Expired - Fee Related
- 2010-03-25 EA EA201190224A patent/EA201190224A1/ru unknown
- 2010-03-25 AU AU2010229795A patent/AU2010229795A1/en not_active Abandoned
- 2010-03-25 US US13/260,378 patent/US9150554B2/en not_active Expired - Fee Related
- 2010-03-25 EP EP10756872A patent/EP2410843A4/en not_active Withdrawn
- 2010-03-25 CA CA2755658A patent/CA2755658A1/en not_active Abandoned
- 2010-03-25 PE PE2011001719A patent/PE20120773A1/es not_active Application Discontinuation
- 2010-03-25 MX MX2011010132A patent/MX2011010132A/es active IP Right Grant
- 2010-03-25 JP JP2012502264A patent/JP5735482B2/ja not_active Expired - Fee Related
- 2010-03-25 BR BRPI1012282A patent/BRPI1012282A2/pt not_active IP Right Cessation
- 2010-03-26 TW TW099109325A patent/TW201038560A/zh unknown
- 2010-03-29 AR ARP100101000A patent/AR076164A1/es unknown
-
2011
- 2011-09-18 IL IL215202A patent/IL215202A0/en unknown
- 2011-09-26 CL CL2011002377A patent/CL2011002377A1/es unknown
- 2011-10-24 ZA ZA2011/07753A patent/ZA201107753B/en unknown
- 2011-10-27 CO CO11145231A patent/CO6450600A2/es active IP Right Grant
-
2012
- 2012-06-18 HK HK12105945.1A patent/HK1166446A1/xx not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| KR20110131312A (ko) | 2011-12-06 |
| AU2010229795A1 (en) | 2011-10-13 |
| US20120040962A1 (en) | 2012-02-16 |
| WO2010111534A1 (en) | 2010-09-30 |
| TW201038560A (en) | 2010-11-01 |
| ZA201107753B (en) | 2012-07-25 |
| PE20120773A1 (es) | 2012-07-19 |
| CA2755658A1 (en) | 2010-09-30 |
| MX2011010132A (es) | 2011-10-14 |
| JP5735482B2 (ja) | 2015-06-17 |
| CL2011002377A1 (es) | 2012-01-20 |
| CN102427726A (zh) | 2012-04-25 |
| EP2410843A4 (en) | 2012-08-08 |
| JP2012522003A (ja) | 2012-09-20 |
| SG174883A1 (en) | 2011-11-28 |
| BRPI1012282A2 (pt) | 2015-09-22 |
| EA201190224A1 (ru) | 2012-03-30 |
| CN102427726B (zh) | 2014-10-08 |
| EP2410843A1 (en) | 2012-02-01 |
| HK1166446A1 (en) | 2012-11-02 |
| CO6450600A2 (es) | 2012-05-31 |
| IL215202A0 (en) | 2011-12-29 |
| US9150554B2 (en) | 2015-10-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR076164A1 (es) | Inhibidores de anillos fusionados de hepatitis c | |
| AR084720A1 (es) | Inhibidores de anillos fusionados triciclicos de hepatitis c | |
| AR080264A1 (es) | Inhibidores ns5a de vhc | |
| AR081831A1 (es) | Inhibidores de la proteina ns5a del virus de la hepatitis c (vhc) | |
| AR080263A1 (es) | Inhibidores ns5a de vhc | |
| AR084388A1 (es) | Compuestos nitrogenados heterociclicos inhibidores de la replicacion del vhc y composiciones farmaceuticas que los contienen | |
| AR081848A1 (es) | Inhibidores de la proteina ns5a del vhc | |
| AR058776A1 (es) | Compuesto de piridina condensado | |
| AR091790A1 (es) | Derivados de isoquinolin-1-ona y sus usos | |
| AR082885A1 (es) | Compuestos y composiciones para la inhibicion de nampt | |
| AR058700A1 (es) | Compuestos heterociclicos como bloqueadores del canal de sodio epitelial | |
| ES2655391T3 (es) | Inhibidores isoindolinona de fosfatidilinositol 3-quinasa | |
| AR084280A1 (es) | Compuestos heterociclicos nitrogenados sustituidos fusionados en posicion 6,6 y usos de los mismos | |
| AR054369A1 (es) | Compuestos de imidazol condensado y su uso como inhibidores de aldosterona sintasa | |
| AR073315A1 (es) | Compuestos heterociclicos antivirales | |
| AR060173A1 (es) | Derivados de piridina y de pirimidina como antagonistas del mglur2, metodos para su preparacion, composiciones farmaceuticas que los contienen y su uso en la fabricacion de medicamentos para el tratamiento de trastornos del snc. | |
| CO5011121A1 (es) | Derivados de isotiazol utiles como agentes anticancerosos | |
| AR076170A1 (es) | Derivados heterociclicos imidazolicos y/o oxazolicos utiles como agentes antivirales para hepatitis c y composiciones farmaceuticas que los comprenden. | |
| CO6241101A2 (es) | Derivados de quinolina como inhibidores de la p13 quinasa | |
| AR077598A1 (es) | Compuestos heterociclicos fusionados como modulares de canales ionicos | |
| PE20110196A1 (es) | 5-alquinil-pirimidinas | |
| AR054529A1 (es) | Derivados de benzazepina como moduladores del receptor de 5-hidroxi-triptamina 6 | |
| CO6180430A2 (es) | Analogos tiofeno para el tratamiento o prevencion de infecciones por flavivirus | |
| BRPI0909731A2 (pt) | derivados de carbazol inibidores de hsp90, composições que os contêm e a respectiva utilização | |
| AR068376A1 (es) | Amidas heterociclicas utiles para inhibir la via hedgehog. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |